Previous studies have demonstrated that higher serum IGFBP-rp1 is involved in the early defect of insulin actions; therefore, it serves as a marker of insulin resistance, metabolic syndrome, T2DM, and related cardiovascular complications [41]. This evidence concerns the gene INS and type 2 diabetes mellitus.